Mycoplasma is a well-recognised pathogen that colonises mucosal surfaces of humans and animals. Mycoplasma pneumoniae infects the upper and lower respiratory tracts of children and adults, leading to a wide range of respiratory and non-respiratory clinical conditions. M. pneumoniae infection is frequently considered in the differential diagnosis of patients with respiratory illnesses, and is commonly managed empirically with macrolides and fluoroquinolones. This contrasts with patients who present with nonrespiratory symptoms in the context of a recent or current unrecognised M. pneumoniae infection, for whom this pathogen is rarely considered in the initial differential diagnosis. This review considers the microbiological, epidemiological, pathogenic and clinical features of this frequent pathogen that need to be considered in the differential diagnosis of respiratory and non-respiratory infections.
I N T R O D U C T I O N
Recognition of Mycoplasma as a bacterial pathogen took many years of intense clinical and research work. The first published report concerning Mycoplasma came from the French scientists Nocard and Roux [1] , who in 1898 described the isolation, culture and infectivity of a microorganism associated with contagious bovine peri-pneumonia, later named Mycoplasma mycoides. No reports concerning Mycoplasma in humans appeared until 1942, when Eaton et al. [2] described the isolation of a filterable agent recovered from the sputum of patients with primary atypical pneumonia. This agent, later named the Eaton agent, was isolated from tissue cultures and infected rodents, with the latter subsequently developing a lung pathology similar to that observed in humans. Finland et al. [3] demonstrated that serum from patients with primary atypical pneumonia contained cold agglutinins capable of neutralising the Eaton agent. For many years, the Eaton agent was believed to be a virus particle rather than a bacterium [4] . The absence of a cell wall, which gives Mycoplasma a pleomorphic phenotype and the ability to pass through viral filters, as well as the difficulty of growing this organism in cell-free culture conditions, supported the hypothesis of the viral nature of the Eaton agent for 20 years. Important developments during the 1960s included the isolation of the Eaton agent from tissue culture cells and, more importantly, from cell-free cultures, thus demonstrating the bacterial nature of the Eaton agent [5] . Induction of atypical pneumonia in volunteers inoculated with purified isolates of the Eaton agent provided proof that this bacterial pathogen, later named Mycoplasma pneumoniae, was an aetiological agent of atypical pneumonia in humans [6] .
M. pneumoniae is now known to be a frequent respiratory pathogen in children as well as in adults. M. pneumoniae infects the upper and lower respiratory tracts, leading to upper respiratory tract infection, bronchiolitis, tracheobronchitis, bronchitis and community-acquired pneumonia. It is also associated with asthma exacerbations [7] . Interestingly, Mycoplasma respiratory tract infections are associated with non-respiratory symptoms in many cases, manifesting in the skin, mucosas, central nervous system (CNS) and other tissues. Improved familiarity with clinical extrapulmonary manifestations of M. pneumoniae infection may improve diagnosis and help to ensure appropriate treatment.
M I C R O B I O L O G Y
Mycoplasma belongs to the class Mollicutes, which includes organisms lacking the genes necessary to synthesise peptidoglycan cell walls. The class Mollicutes comprises four orders, five families, eight genera and 200 species [8, 9] . Mollicutes are related phylogenetically to Gram-positive bacteria, based on 16S rRNA phylogenetic analysis. Despite the genetic relatedness of Mycoplasma to ancestral Gram-positive bacteria, the absence of a cell wall prevents successful staining with Gram's strain. The Mycoplasma chromosome is circular and c. 500 kb in size, making Mycoplasma one of the smallest autonomously replicating living organisms in nature [10] .
The absence of a rigid cell wall makes Mycoplasma pleomorphic and able to cross filters that are otherwise permeable only to viruses. Mycoplasma may have a spherical shape under hypotonic conditions, and an irregular shape under hypertonic conditions; dehydration kills Mycoplasma [11, 12] . All members of the Mycoplasma genus require sterols for growth. These essential components of the Mycoplasma membrane provide support to this osmotically fragile organism [13] .
Mycoplasma genomic DNA lacks almost all the genes necessary for the biosynthesis of aminoacids, fatty acids, co-factors and vitamins, and the organism therefore depends on the host for a supply of metabolic precursors [11] . This limited biosynthetic potential means that mycoplasmas are obligatory parasites with strict host and tissue specificities [14] . Their host range includes plants, insects, animals and humans [15] . In humans, some colonising species behave as normal flora (e.g., Mycoplasma salivarium, Mycoplasma orale), while other species are clearly established pathogens (e.g., M. pneumoniae, Mycoplasma genitalium, Mycoplasma hominis, Mycoplasma fermentans and, possibly, Mycoplasma penetrans) [9, 16] . M. pneumoniae may elaborate capsular material around the cell membrane [17] . Little is known concerning capsular expression, the genes necessary for its biosynthesis, and its role in M. pneumoniae pathogenesis. Table 1 summarises the most important biological characteristics of M. pneumoniae.
P A T H O G E N E S I S
The Mollicutes are primarily mucosa-associated organisms that reside in the host's respiratory and urogenital tracts in close association with epithelial cells, yet are located extracellularly [18] . There are several proposed mechanisms to explain pathogenicity, including competition for precursors, adherence to cells, fusion to cell membranes, cell invasion and cytotoxicity [11, 14] .
Cyto-adherence and its importance in pathogenesis
M. pneumoniae colonises the respiratory epithelium by attaching to cilia [19] . Mycoplasma cytoadherence to the respiratory tract is the initial event leading to colonisation, infection and lung tissue damage [14] . P1, P30, P116 and HMW1-3 comprise a group of membrane proteins associated with Mycoplasma cyto-adherence [20] [21] [22] , some of which concentrate on a single attachment tip organelle ( Fig. 1) found at the surface of Mycoplasma [23] [24] [25] . Alteration or the absence of any of these proteins results in Mycoplasma becoming avirulent [26, 27] .
Cell invasion and pathogenesis
Although M. pneumoniae is primarily an extracellular pathogen that depends on close host-cell contact for survival, in-vitro studies have shown that it can penetrate cell membranes and invade cells [28] . Another species, M. penetrans, is also Pleomorphic because of the absence of a cell wall Tip structure for attachment Host Humans able to invade tissue culture cells, and is a recognised pathogen that infects the genitourinary tract of patients with AIDS [29, 30] . In-vitro evidence indicates that Mycoplasma can enter tissue culture cells within 2 h, and can remain intracellular for >7 days. Confocal microscopy has identified Mycoplasma in perinuclear regions and throughout the cell cytoplasm [31] . The interaction between Mycoplasma and epithelial cells triggers signals that induce recruitment of cytoskeletal proteins, including tubulin and a-actinin. Furthermore, it has been shown that M. penetrans also binds the extracellular matrix protein fibronectin, suggesting that signalling mediated by integrin-fibronectin may induce internalisation of Mycoplasma [32] .
Cytotoxicity mediated by Mycoplasma
Mycoplasma internalisation into host cells is not necessary for the initiation of local cytotoxic events and clinical manifestations of disease. Cytopathic changes can be related to the local damage following cyto-adherence. Close contact between Mycoplasma and host tissue allows local disruption and cytotoxicity through the release of enzymic and cytolytic metabolites directly on to the cell [14] . Fusion of Mycoplasma membrane to host-cell membrane may result in the release of hydrolytic enzymes produced by Mycoplasma, as well as the insertion of bacterial membrane components into the host cell membrane.
Mycoplasma nucleases have been shown to induce inter-nucleosomal DNA fragmentation in cultured cells [33] , and an ADP-ribosyltransferase toxin with homology to pertussis toxin was reported to induce vacuolisation of epithelial cells [34] . Several epithelial cell proteins are targeted by the vacuolising toxin, although none have so far been identified.
Immune response and cytokine production
Mycoplasma activates the immune system by inducing B-and T-lymphocyte proliferation, secretion of major histocompatibility complex class I and II proteins, and release of multiple cytokines (e.g., interleukins, interferons, tumour necrosis factor and colony-stimulating factors). These effects may result in local or systemic manifestations in the infected host. Cytokines are important mediators of inflammation in respiratory and non-respiratory tissues, as demonstrated by in-vivo and in-vitro studies ( Table 2) . Mycoplasma spp. induce cytokines in tissue culture cells, experimental animals and humans [19, [35] [36] [37] . Mycoplasma-mediated cytokine release in infected children is associated with worsening asthma symptoms [7] . Studies in mice indicate that the T-helper 1 type of immune response induced by Mycoplasma is responsible for increased airway obstruction and elevated airway hyper-responsiveness [38] . The ciliated airway epithelium is the primary site of Mycoplasma infection, and is the principal source of a variety of cytokines with a pro-inflammatory role [39] . Evidence suggests that cell surface lipoproteins are the preferential target of the humoral immune response [40] .
Evasion and suppression of the immune response
The major mechanisms implicated in the evasion of the immune response by Mycoplasma include molecular mimicry, survival within cells and phenotypic plasticity. Some Mycoplasma spp. may undergo changes in the lipoprotein repertoire expressed in the cell membrane as a way of coping with a fluctuating environment and the host immune response [40] . Furthermore, M. pneumoniae may induce transient depression of T-lymphocyte function and depletion of CD4 + T-cells [41, 42] . Induction of transient anergy has also been described during the acute phase of Mycoplasma infection [43] . Similarly, a study in children acutely infected by M. pneumoniae reported a temporary suppression of the immune system by mechanisms as yet unknown [44] .
M. pneumoniae can be transmitted by aerosols from person to person. Individuals with active Mycoplasma infection carry organisms in the nose, throat, trachea and sputum, with transmission facilitated by coughing. The incubation period varies from 1 to 3 weeks, although it is sometimes as short as 4 days [9, 45] . During epidemics, the presence of different subtypes may explain the lack of a protective immune response against subsequent infection [46] . Studies in outpatient clinics in Seattle, WA, USA reported that M. pneumoniae infection rates varied from 2% in endemic years to 35% in epidemic periods. Epidemics occurred every 4-7 years. A higher proportion of children aged 5-9 years developed pneumonia than did adolescents aged 15-19 years [47] . Mycoplasma outbreaks tend to occur in crowded environments or institutions such as hospitals, military camps and college dormitories [48, 49] . Studies using PCR screening have indicated that a possible carrier status may provide a reservoir for these organisms. Although M. pneumoniae is not part of the normal flora, and its presence is frequently associated with infection, the microorganism may persist inside the host's respiratory tract for variable periods even after the clinical manifestations have resolved [50] . Furthermore, M. pneumoniae infection tends to be more severe among immunosuppressed individuals, including individuals with humoral immune defects. Table 3 ). The development of new techniques for the detection of M. pneumoniae has revealed that this organism can also be found in extra-pulmonary tissues [16] , with c. 25% of individuals infected with M. pneumoniae experiencing extra-pulmonary complications [8] . Extra-pulmonary manifestations could occur before, after, during or in the absence of respiratory symptoms. Extra-pulmonary manifestations may occur not less than 3 days after the onset of respiratory disease, and for 2-3 weeks after the respiratory disease has resolved [53] . Whether infection itself or postinfection inflammation is responsible for the extra-pulmonary clinical manifestations is currently under investigation.
C L I N I C A L M A N I F E S T A T I O N S
While M. pneumoniae most commonly infects the respiratory tract, infections caused by Mycoplasma spp. other than M. pneumoniae have been described in blood, brain tissue, cerebrospinal fluid (CSF), skin, the urogenital tract, heart and joints [9, 16, 29, 54, 55] .
Skin and mucosal infections
Among patients with M. pneumoniae infection, c. 25% may have dermatological manifestations, making these some of the most common complications of this infection [43] . A wide range of skin and mucosal manifestations has been described in the literature (Table 3 ). There is a well-known association between Mycoplasma and Stevens-Johnson syndrome, erythema multiforme and toxic epidermal necrolysis [56, 57] . M. pneumoniae is the most common infectious agent associated with
Stevens-Johnson syndrome [58, 59] . Some cases of Stevens-Johnson syndrome were reported to exclusively affect mucosal membranes, leaving the skin intact [57, 59] . It is unclear at present whether this entity is a variant of Stevens-Johnson syndrome or a new entity. Patients with oral, as well as genitourinary, mucosal lesions, generally manifest with fever and generalised fatigue. Antimicrobial therapy rapidly resolves the clinical condition.
The exact mechanism of skin and mucosal disease is unknown, but immune complex-mediated vascular injury, cell-mediated immune response and cytotoxic injury to epithelial cells, and autoimmune mechanisms have all been suggested [57] . While M. pneumoniae has been detected directly in cutaneous lesions, there is no evidence that Mycoplasma causes such lesions directly.
CNS manifestations
CNS manifestations are the most common extrapulmonary complications of M. pneumoniae infection. Encephalitis and meningoencephalitis are most common, followed by polyradiculitis and aseptic meningitis [41, 51] . Frequently, a manifest respiratory infection precedes the CNS symptoms. The mean interval between the onset of respiratory symptoms and CNS manifestations is 9.6 days (range 2-14 days) [41, 52] . M. pneumoniae infection should be routinely considered in the differential diagnosis of patients with CNS manifestations, especially if associated with pneumonia [60] . Table 3 lists the neurological conditions associated with Mycoplasma infection.
Among serologically confirmed M. pneumoniae infections that require hospitalisation, c. 1-10% are associated with neurological manifestations. The overall incidence is <0.1%, although the exact incidence of M. pneumoniae-associated M. pneumoniae is a major cause of encephalitis in children. Children aged <10 years are affected more frequently than adults. Severe presentations require intensive care management in up to 30% of cases with CNS involvement. Long-term neurological sequelae are documented in about one-third of serologically confirmed cases of encephalitis [61] . A prospective 5-year study of children with acute encephalitis found evidence of M. pneumoniae infection in 31% of all cases, with M. pneumoniae being the probable cause of encephalitis in 6.9% of cases, based on PCR detection of Mycoplasma DNA in CSF and positive serological results. Respiratory symptoms were absent in 36% of patients with probable M. pneumoniae encephalitis [62] .
Acute transverse myelitis and acute disseminated encephalomyelitis are among the most severe CNS manifestations of M. pneumoniae infections. CNS symptoms and signs associated with M. pneumoniae infections usually resolve completely; however, a persistent neurological deficit has been described in up to one-third of patients [41, 60] .
The pathogenesis of CNS disease associated with M. pneumoniae remains unknown, and further research is underway to elucidate the possible mechanism(s) of pathogenesis. Direct invasion of the CNS by M. pneumoniae has been implicated in early-onset encephalitis, but the only evidence for this has been PCR-based detection of M. pneumoniae in CSF [52, 53, 63] . While detection of M. pneumoniae in the CNS may be the result of migration of antigen-presenting cells from pulmonary sites carrying Mycoplasma DNA [64] , it is known that M. hominis actively crosses the blood-brain barrier to cause brain abscesses [65] . Neurotoxin may also be implicated in the pathogenesis of CNS disease, and an M. pneumoniae virulence factor with ADP-ribosyltransferase activity and homology to pertussis toxin has been described that leads to epithelial cell damage in vitro [34] . This toxin may have systemic effects that include the CNS. More studies are necessary to elucidate the role of this toxin in Mycoplasma extra-pulmonary disease. Immune response-mediated damage, by bacteria-induced immunosuppression, immune complexes or autoimmune mechanisms, may better explain late-onset encephalitis. Molecular mimicry and the production of anti-human antibodies have been associated with Mycoplasma infections and antibodies against brain tissue antigens that may contribute to the neurological injury [66] . Lastly, thrombosis and a hyper-coagulable state may lead to intravascular coagulation and thromboembolic CNS complications in association with Mycoplasma [41, 52] . The peripheral nervous system may also be involved during M. pneumoniae infection in children [67] and young adults. Studies in individuals aged <35 years with Guillain-Barré syndrome have revealed a significant association with M. pneumoniae infection [68] .
D I A G N O S I S
M. pneumoniae infections cannot be diagnosed by clinical findings alone, especially when they present with extra-pulmonary symptoms. Before the availability of new technologies, cold agglutinins were used to confirm a diagnosis of M. pneumoniae infection. Cold agglutinins are IgM antibodies directed to antigen 1 on erythrocytes. They are produced 1 or 2 weeks after infection in 50% of patients and may persist for several weeks. Lack of sensitivity and specificity render cold agglutinins irrelevant for diagnosis, as they may also be present in infections caused by viruses and other bacteria [52, 69, 70] . While culture is considered to be the reference standard for diagnosis, it is expensive and time-consuming, and requires specialised media and technical expertise. Furthermore, culture is not available except in reference laboratories or large medical centres ( Table 4 ). Diagnosis of M. pneumoniae infection is usually performed by serological methods, such as passive agglutination, complement fixation and ELISA. A combination of PCR and serology is recommended for reliable diagnosis [71] . Serological tests for anti-Mycoplasma antibody represent the most common method for retrospective diagnosis of Mycoplasma infections. Evidence of seroconversion by collection of acute and convalescent sera is the optimal method for retrospective Mycoplasma diagnosis. Seroconversion is defined as a four-fold increase in titre between acute and convalescent sera, or a single high anti-Mycoplasma complement fixation antibody titre of >1:128. False-positive results caused by cross-reactions between antigens can occur.
Serological testing is often hampered by interspecies cross-reactions and even non-specific reactions [41, 72] . The sensitivity and specificity of passive agglutination with single serum samples varies with the titre cut-off value used. It is suggested that a titre of 1:80 or 1:160 is useful for the diagnosis of M. pneumoniae infection in children. Passive agglutination serology using paired sera shows good agreement with PCR results [71] . ELISA is more sensitive than culture for detecting acute infection, has sensitivity comparable to PCR [71] , but may be less sensitive than passive agglutination [71] . Complement fixation tests, indirect immunofluorescent assays and particle agglutination assays have low sensitivity and specificity [52] .
PCR has been recommended for more sensitive detection of M. pneumoniae, especially for patients with neurological and other extra-pulmonary manifestations [41] . PCR uses the same specimens as does culture, but may also detect Mycoplasma in tissue processed for histological examination. The advantages of PCR include high sensitivity and specificity, rapid results, and no requirement for viable microorganisms [8] . However, PCR assays may overestimate the incidence of Mycoplasma infections and, at present, there is no standardised diagnostic method [72, 73] .
T R E A T M E N T
While there is no disagreement concerning the optimum antibiotic management of M. pneumoniae respiratory tract infections, controversy and limited clinical evidence characterises the current situation concerning management of non-pulmonary conditions associated with M. pneumoniae.
Antibiotic management of Mycoplasma respiratory infections
The absence of a cell wall renders these organisms insensitive to b-lactam antibiotics. However, antibiotics acting at the level of protein synthesis or DNA modification molecules are highly effective. Macrolides, tetracyclines and fluoroquinolones eliminate Mycoplasma efficiently both in vivo and in vitro. Macrolides are the antibiotics of choice for treating M. pneumoniae infections in both adults and children. New macrolides are bettertolerated, require fewer doses and have a shorter treatment duration than older compounds.
In the ambulatory setting, it is more practical to provide therapy empirically. However, if the infection requires hospitalisation and the patient has risk-factors, e.g., an underlying condition, or an unfavourable prognosis, diagnostic testing is recommended [74] . Use of tetracycline and fluoroquinolones is limited to adult patients or to patients with an allergy to macrolides. Tetracyclines should not be used in children aged <8 years. Azithromycin is given at recommended doses for 5 days. Other macrolides such as clarithromycin and erythromycin, as well as tetracyclines and fluoroquinolones, usually require longer courses. A potential problem in the antimicrobial management of M. pneumoniae infections is the emergence of macrolide resistance, reported initially in Japan during 2000 [75] . Treatment of children with fluoroquinolones may be possible; however, these agents are not yet approved for use in children by the Federal Drug Administration [76] . While M. pneumoniae infections in the upper respiratory tract may improve following antibiotic treatment, this is not generally recommended, as such infections are usually self-limiting. Some clinicians recommend treatment of acute tonsillo-pharyingitis to prevent the risk of recurrence of respiratory illness [77] .
Management of non-respiratory conditions associated with Mycoplasma infections
Controversies in the management of non-respiratory conditions associated with M. pneumoniae infections result from the limited knowledge of [41, 52, 63] . Case reports suggest that high-dose steroid therapy may reverse neurological manifestations in children. Aggressive therapy with steroids and high-dosage immunoglobulins in children was reported to improve outcome in cases of stroke related to M. pneumoniae infection [53] . Even severe cases of M. pneumoniae pneumonia in children also benefit from the use of steroids in conjunction with antibiotics [43] .
In addition to steroids, other therapies, including plasmapheresis, plasma exchange and intravenous IgG, have been used to treat patients with severe CNS complications. None of these strategies has been tested in randomised double-blind clinical trials, and their benefit therefore remains unclear. Plasmapheresis was reported to be effective in cases of transverse myelitis or polyradiculitis [60] . Despite the absence of evidence, it seems reasonable to consider the use of immunomodulatory therapies, together with antibiotics, in severe cases.
The use of antibiotics for treating CNS conditions associated with M. pneumoniae infection is also reported to have variable results. Treatment with macrolides, tetracyclines, fluoroquinolones and chloramphenicol is limited to case reports involoving severe CNS conditions associated with Mycoplasma infections [78] , and an actual benefit from antibiotic therapy was not demonstrated in most of the cases. The rationale for antibiotic use is based on the PCRbased detection of Mycoplasma DNA in CSF, and the assumption that this DNA is evidence of viable M. pneumoniae cells growing in the CNS. However, microbiological studies have failed to obtain positive M. pneumoniae cultures from CSF, which suggests that other mechanisms of pathogenesis may be involved.
Until more information is available concerning the pathogenesis of M. pneumoniae-associated extra-pulmonary conditions, it seems that supportive treatment remains the most important management approach [45] , with the use of steroids and antibiotics being considered on an individual basis.
C O N C L U S I O N S
Mycoplasmas are fastidious microorganisms that were first identified a century ago and have subsequently been studied extensively both in vivo and in vitro. Advances in laboratory technology have significantly improved the diagnosis of M. pneumoniae respiratory infections and have increased the number of previously unrecognised extra-pulmonary conditions associated with M. pneumoniae infection. However, many questions remain unanswered concerning pathogenesis, the role of host factors in clinical presentation, and the medical management of extra-pulmonary conditions. While clinical and experimental evidence has accumulated concerning the role of M. pneumoniae in activating proinflammatory molecules and tissue inflammation, little is known with respect to the effect of newly described M. pneumoniae virulence factors on direct tissue damage or systemic cytotoxicity. Management of extra-pulmonary conditions is controversial, as neither antibiotics nor antiinflammatory drugs have a clearly demonstrated clinical benefit. Basic research on the molecular biology of Mycoplasma infection will be important in gaining an understanding of the pathogenesis of the diverse clinical conditions associated with these organisms. Furthermore, clinical studies on the epidemiology and clinical management of extra-pulmonary conditions will be essential to better identify patients with conditions that may benefit from antibiotic therapy and those that may benefit from immunomodulatory therapies.
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